Abstract
Gonadotropin-releasing hormone (GnRH) and its analogues have been used clinically to treat a range of hormone-dependent conditions. It is often necessary for large, toxic and expensive drug doses to be administered. Improvements in drug delivery have necessitated new developments in formulation, but these in turn can induce new adverse effects. Immunological neutralisation of GnRH has been examined as a less toxic and cheaper replacement therapy, and has been studied closely in different animal species. However, only a few clinical trials have been carried out with respect to hormone-dependent cancers. Based on clinical trials of the free peptide drug in cancer patients, it would appear that there is an increasing trend towards using GnRH and its analogues in adjuvant therapy and that antibody-based GnRH neutralisation will have a role in this treatment regimen.
Article PDF
Similar content being viewed by others
References
Schally AV, Arimura A, Kastin A. Hypothalamic regulatory hormones. Science 1973; 179: 341–50
Braden TD, Hawes E, Conn PM. Synthesis of GnRH receptors by gonadotrope cell cultures. Endocrine 1989; 125: 1623–9
Conn PM, Huckle WR, Andrews WV, et al. The molecular mechanism of action of GnRH in the pituitary. In: Clarke JH, editor. Recent progress in hormone research. New York: Academic Press, 1987; 43: 29–49
Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogs. Ann Rev Med 1994; 45: 391–405
Matsuo H, Arimura A, Nair RMG, et al. Syntheis of the porcine LH- and FSH-releasing hormone by the solid-phase method. Biochem Biophys Res Commun 1971; 45: 822–7
Schally AV, Arimura A, Kastin AJ, et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinising and follicle stimulating hormones. Science 1971; 173: 1036–8
Geiger R, Konig N, Wissman H, et al. Synthesis and characterisation of a decapeptide having LH-RH-FSH-RH activity. Biochem Biophys Res Commun 1971; 45: 767–73
Kastin AJ, Zarate A, Midgley AR, et al. Ovulation confirmed by pregnancy after infusion of porcine LHRH. J Clin Endocrinol Metab 1971; 33: 980–2
Mortimer CH, McNeilly AS, Fisher RA, et al. Gonadotrophin-releasing-hormone therapy in hypogonadal males with hypothalamic or pituitary dysfunction. BMJ 1974; 4: 617–21
Pelletier G, Cusan L, Auclair C. Inhibition of spermatogenesis in the rat by treatment with (D-Ala6, DES-Gly-NH2 10) LHRH ethylamide. Endocrinology 1978; 103: 641–3
Tcholakian RK, DeLa Cruz A, Chowdhury M, et al. Unusual anti-reproductive properties of the analogue (D-Leu6 DES-gly-NH2 l0)-luteinising hormone releasing hormone ethylamide in male rats. Fertil Steril 1978; 30: 600–3
Lemay A, Sandow J, Quesnel G. Escape from the down-regulation of the pituitary-ovarian axis following decreased infusion of luteinising hormone releasing hormone agonist. Fertil Steril 1988; 49: 802–8
Schally AV, Kastin AJ, Coy DH. LHRH and its analogues: recent basic and clinical investigation. Int J Fertil 1976; 21: 1–30
Henzl MR. Gonadotropin-releasing hormone and its analogues. From laboratory to bedside. Ballieres Clin Obstet Gynaecol 1993; 36: 617–35
Garnick MB. Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology 1997; 49: 5–15
Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15: 1013–21
Fair WR, Cookson MS, Stroumbakis N, et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997; 49: 46–55
Brandstedt S, Busch C, Hellstrom M, et al. Neo-adjuvant GnRH therapy and radical prostatectomy: effects on tumorous and benign tissue volumes — a morphometric study. Urol Res 1997; 25: 43–7
Shaw RW. LHRH analogues in the treatment of endometriosis — comparative results with other treatments. Ballieres Clin Obstet Gynaecol 1988; 2: 659–75
Barbieri RL. GnRH agonists: treatment of endometriosis. Ballieres Clin Obstet Gynaecol 1993; 36: 636–41
West CP. LHRH analogues in the management of uterine fibroids, premenstrual syndrome and breast malignancies. Ballieres Clin Obstet Gynaecol 1988; 2: 689–709
Mortola JF. Application of GnRH analogues in treatment of PMS. Ballieres Clin Obstet Gynaecol 1993; 36: 753–63
Shaw RW. GnRH analogue treatment of fibroids. Ballieres Clin Obstet Gynaecol 1988; 2: 245–68
Maheux R. Treatment of uterine leiomyomata: past, present and future. Horm Res 1989; 32: 125–33
Nakamura Y, Yoshimura Y. Treatment of uterine leiomyomas in perimenopausal women with GnRH analogues. Ballieres Clin Obstet Gynaecol 1993; 36: 660–7
Gadducci A, Genazzani AR. Steroid hormones in endometrial and breast cancer. Review. Eur J Gynaecol Oncol 1997; 18: 371–8
Gonzalez A, Allen AF, Post K, et al. Immunological approaches to contraception in dogs. J Reprod Fertil Suppl 1989; 39: 189–98
Wu FCW. Male Contraception. Ballieres Clin Obstet Gynaecol 1996; 10: 1–23
Stovall TG. GnRH agonists: utilisation before hysterectomy. Ballieres Clin Obstet Gynaecol 1993; 36: 642–9
Friedman AJ. 1993 Use of GnRH agonists before myomectomy. Ballieres Clin Obstet Gynaecol 1993; 36: 650–9
Fleming R, Coutts JRT. LHRH analogues for ovulation induction, with particular reference to polycystic ovary syndrome. Ballieres Clin Obstet Gynaecol 1988; 2: 677–87
Benshushan A, Ezra Y, Simon A. The effect of gonadotorphin releasing hormone agonist on embryo quality and pregnancy rate following cryopreservation. Fertil Steril 1993; 59: 1065–9
Itskovitz-Eldor J, Levron J, Kol S. Use of GnRH analogues to cause ovulation and prevent the ovarian hyperstimulation syndrome. Ballieres Clin Obstet Gynaecol 1993; 36: 711–8
Chang RJ, Laufer LR, Meldrum DR, et al. Steroid reception in polycystic ovarian disease after ovarian suppression by a long acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 1983; 56: 897–903
Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long-acting agonist of gonadotropin-releasing hormone (GnRH) in the treatment of precocious puberty. Endocr Rev 1986; 7: 24–33
Furr BJ, Nicholson RI. Use of analogues of luteinising hormone-releasing hormone for the treatment of cancer. J Reprod Fertil 1982; 64: 529–39
Klijn JG. Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med Oncol Tumor Pharmacother 1984; 1: 123–8
Adelson MD, Reece MT. Effects of GnRH analogues on ovarian epithelial tumours. Ballieres Clin Obstet Gynaecol 1993; 36: 690–700
Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 1994; 9: 1364–79
Sismondi P, Biglia N, Defabiani E. GnRH analogs in benign breast disease and breast cancer chemoprevention. A challenge for the year 2000. Eur J Gynaecol Oncol 1994; 15: 108–14
Bartelink H, Rubens RD, van der Schueren E, et al. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J Clin Oncol 1997; 15: 207–15
Redding TW, Schally AV. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A 1984; 81: 248–52
Klibanski A, Jameson JL, Biller BMK, et al. Gonadotropin and α-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone secreting pituitary tumors. J Clin Endocrinol Metab 1989; 68: 81–5
Kimmick GG, Muss HB. Endocrine therapy in metastatic breast cancer. Cancer Treat Res 1998; 94: 231–54
Lemay A. Clinical appreciation of LHRH analogue formulations. Horm Res 1989; 32: 93–101
Labrie F, Dupont A, Belanger A, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrinol Rev 1986; 7: 67–74
Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 NO MO prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997; 49: 65–9
Labrie F, Cusan L, Gomez JL, et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology 1997; 49: 56–64
Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol 1998; 159: 950–4
Labrie F, Dupont A, Belanger A, et al. Simultaneous administration of pure anti-androgens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci U S A 1984; 81: 3861–3
Fraser HM. LHRH analogues: their clinical physiology and delivery systems. Ballieres Clin Obstet Gynaecol 1988; 2: 639–58
Petri W, Seidel R, Sandow J. A pharmaceutical approach to long-term therapy with peptides. In Labrie F, Belanger A, Dupont A, editors. LHRH and its analogues. Amsterdam: Elsevier, 1984: 23–44
Fraser HM, Baird DT. Clinical applications of LHRH analogues. Ballieres Clin Endocrinol Metab 1987; 1: 43–70
MacLeod TL, Eisen A, Sussman GL. Anaphylactic reaction to synthetic luteinising hormone releasing hormone. Fertil Steril 1987; 48: 500–2
Qayum A, Gullick WJ, Waxman J. Gonadotrophin-releasing hormone: physiological significance and relevance to cancer. Prog Growth Factor Res 1991; 3: 115–30
Rivier J, Jiang GG, Lahrichi SL, et al. Dose relationship between GnRH antagonists and pituitary suppression. Hum Reprod 1996; 11: 133–47
Goodman GE. The clinical evaluation of cancer chemopreventative agents: defining and contrasting phase I, II, and III objectives. Cancer Res 1992; 52: 2752–7
Kelloff GJ, Boone CW, Steele VE, et al. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res 1994; 54: 2015–24
Hoskinson RM, Rigby RDG, Mattner PE, et al. Vaxstrate: an anti-reproductive vaccine for cattle. Aust J Biotech 1990; 4: 166–70
Arimura A, Sato H, Kumadaka T, et al. Production of anti-sera to LH-releasing hormone (LHRH) associated with gonadal atrophy in rabbits: development of radioimmunassays for LHRH. Endocrinology 1973; 99: 291–303
McCormack JT, Plant TM, Hess DL, et al. The effect of luteinizing hormone releasing hormone (LHRH) antiserum administration on gonadotropin secretion in the rhesus monkey. Endocrinology 1977; 100: 663–7
Sakai T, Inoue K, Hasegawa Y, et al. Effect of passive immunization to gonadotropin-releasing hormone (GnRH) using GnRH antiserum on the mitotic activity of gonadotrophs in castrated male rats. Endocrinology 1988; 122: 2803–8
Carelli C, Audibert F, Gaillard J, et al. Immunological castration of male mice by a totally synthetic vaccine administered in saline. Proc Natl Acad Sci U S A 1982; 79: 5392–5
Silversides DW, Allen AF, Misra V, et al. A synthetic luteinizing hormone releasing hormone vaccine. I. Conjugation and specificity trials in BALB/c mice. J Reprod Immunol 1988, 13; 249–61
Silversides DW, Allen AF, Misra V, et al. A synthetic luteinizing hormone releasing hormone vaccine II. Temporal aspects of titer development and formulation trials in BALB/c mice. J Reprod Immunol 1988; 14: 47–58
Awoniyi CA, Santulli R, Chandrashekar V, et al. Quantitative restoration of advanced spermatogenic cells in adult male rats made azoospermic by active immunization against luteinizing hormone or gonadotropin-releasing hormone. Endocrinology 1989;125: 1303–9
Feurst J, Fiebiger E, Mack D, et al. The effect of active immunization against gonadotropin-releasing hormone on the ultrastructure of the rat ventral prostate. Urol Res 1994; 22: 107–13
Meloen RH, Turkstra JA, Lankhof H, et al. Efficient immunocastration of male piglets by immunoneutralization of GnRH using a new GnRH-like peptide. Vaccine 1994; 12: 741–6
Kerdelhue B, Jutisz M, Gillessen D, et al. Obtention of antisera against a hypothalamic decapeptide (luteinising hormone follicle stimulating hormone releasing hormone) which stimulated the release of pituitary gonadotrophins and development of its radioimmunoassay. Biochim Biophys Acta 1973; 297: 540–8
Pique L, Cesselin F, Strauch G, et al. Specificity of anti-LH-RH antisera induced by different immunogens. Immunochem 1978; 15: 55–60
Ravdin PM, Jordan VC. Active immunization to luteinizing hormone releasing hormone to inhibit the induction of mammary tumors in the rat. Life Sci 1988; 43: 117–23
Jeyashankar R, Chaudhary MK, Singh O, et al. Semisynthetic anti-LHRH vaccine causing atrophy of the prostate. Prostate 1989; 14: 3–11
Adams TE, Adams BM. Reproductive function and feedlot performance of beef heifers actively immunized against GnRH. J Animal Sci 1990; 68: 2793–805
Urbanski HF. Monoclonal antibodies to luteinising hormone releasing hormone: production, characterisation and immunocytochemical application. Biol Reprod 1991; 44: 681–8
Ferro VA, O’Grady JE, Notman J, et al. Immunological castration using a gonadotrophin-releasing hormone analogue conjugated to PPD. Food Agri Immun 1995; 7: 259–72
Ferro VA, O’Grady JE, Norman J, et al. An investigation into the immunogenicity of a GnRH analogue in male rate: a comparison of the toxicity of various adjuvants used in conjunction with GnRH-glycys, Vaccine 1996; 14: 451–7
Brewer JM, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumen. Immunology 1992; 75: 570–5
Turk JL, Parker D. Granuloma formation in normal guinea pigs injected intradermally with aluminium and zirconium compounds. J Invest Dermatol 1977; 68: 336–40
Bomford R. Relative adjuvant efficacy of aluminium hydroxide and saponin is related to the immunogenicity of the antigen. Int Arch Allergy Appl Immunol 1984; 75: 570–5
Gupta RK, Siber GR. Adjuvants for human vaccines — current status, problems and future prospecte. Vaccine 1995; 13: 1263–76
Alving CR, Verma JN, Ras U, et al. Liposomes containing lipid A as a potent non-toxic adjuvant. Res Immunol 1992; 143: 197–8
Eldridge JH, Gilley RM, Staas JK, et al. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr Top Microbiol Immunol 1989; 146: 59–66
Men Y, Thomasin C, Merkle HP, et al. A single administration of tetanus toxoid in biodegradable microspheres elicite T cell and antibody responses similar or superior to those obtained with aluminium hydroxide. Vaccine 1995; 13: 683–9
Kersten GF, Donders D, Akkermans A, et al. Single shot with tetanus toxoid in biodegradable microspheres protects mice despite acid-induced denaturation of the antigen. Vaccine 1996; 14: 1627–32
Diwan M, Dawar H, Talwar GP. Induction of early and bioeffective antibody response in rodents with the luteinizing hormone-releasing hormone vaccine given as a single dose in biodegradable microspheres along with alum. Prostate 1998; 35: 279–84
Gupta RK, Chang AC, Siber GR. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Dev Biol Stand 1998; 92: 63–78
Hoglund S, Dalsgaard K, Lovgren K, et al. ISCOMS and immunostimulation with viral antigens. In: Harris JR, editor. Subcellular biochemistry. New York: Plenum Press, 1989; 39–68
Larsson M, Lovgrn K, Morein B. Immunopotentiation of synthetic oligopeptides by chemical conjugation to iscoms. J Immunol Methods 1993; 162: 257–6
Audibert FM, Lise CD. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993; 14: 281–4
Toth I. A novel chemical approach to drug delivery: lipid amino acid conjugates. J Drug Target 1994; 2: 217–39
Hosmalin A, Carelli C, Gaillard J, et al. Structural requirements for the induction of ‘immunological castration’ by linear monomeric LHRH-lys-MDP administered in saline. Clin Immunol Immunopath 1987; 45: 447–60
Aguado MT. Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems. Vaccine 1993; 11: 596–597
Singh M, Singh O. Talwar GR. Biodegradable delivery system for a birth control vaccine: immunogenicity studies in rats and monkeys. Pharm Res 1995; 12: 1796–800
Newman MJ, Actor JK, Balusubramanian M, et al. Use of non-ionic block copolymers in vaccines and therapeutics. Crit Rev Ther Drug Carrier Syst 1998; 15: 89–142
Morrison CA, Fishleigh RV, Ward DJ, et al. Computer aided design and physiological testing of a LHRH analogue for ‘adjuvant-free’ immunocastration. FEBS Lett 1987; 214: 65–73
Ladd A, Tsong YY, Lok J, et al. Active immunization against LHRH: I. Effects of conjugation site and dose. Am J Reprod Immunol 1990; 22: 56–63
Desmukh US, Talwar GP, Gupta SK. IgG subclass distribution of anti-hCG and anti-diphtheria toxoid antiodies in women immunized with a hCG based immunocontraceptive vaccine. J Reprod Immunol 1994; 26: 65–72
Jeffcoate IA, Foster JP, Crighton DB. Effects of active immunisation of ewes against synthetic luteinising hormone releasing hormone. Theriogenology 1978; 10: 323–5
Nicholson RI, Golder MP. The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours. Eur J Cancer 1975; 11: 571–9
Ferro VA, Stimson WH. Immunoneutralisation of gonadotrophin releasing hormone: a potential treatment for oestrogen-dependent breast cancer. Eur J Cancer 1997; 33: 1468–78
Thau R. Anti-LHRH and anti-pituitary gonadotrophin vaccines: their development and clinical applications. Scand J Immunol 1992; 36: 127–30
Ferro VA, O’Grady JE, Notman J, et al. Development of a hormone neutralizing vaccine, using GnRH-glycys-PPD, for use in the treatment of oestrogen-dependent disorders. Ther Immunol 1995; 2: 147–57
Awoniyi CA, Reece MS, Hurst BS, et al. Maintenance of sexual function with testosterone in the gonadotropin-releasing hormone-immunized hypogonadotropic infertile male rat. Biol Reprod 1993; 49: 1170–6
Awoniyi CA, Kim WK, Hurst BS, et al. Immunoneutralization of gonadotropin-releasing hormone and subsequent treatment with testosterone Silastic implants in rats: an approach toward developing a male contraceptive. Fertil Steril 1992; 58: 403–8
McLachlan RI, Wreford NG, Tsonis C, et al. Testosterone effects on spermatogenesis in the gonadotropin-releasing hormone-immunized rat. Biol Reprod 1994; 50: 271–80
Fraser HM, Baker TG. Changes in the ovaries of rats after immunization against luteinizing hormone releasing hormone. J Endocrinol 1978; 77: 85–93
Kawakami M, Higuchi T. Effect of active and passive immunisation with LHRH on gonadotrophin secretion and reproductive function in female rats. Acta Endocrinologica 1979; 91: 616–28
Takahashi M, Ford JJ, Yoshinaga K, et al. Active immunisation of female rats with luteinising hormone releasing hormone (LHRH). Biol Reprod 1978; 17: 754–61
Okon E, Livni N, Koch Y. Immunization against gonadotrophin-releasing hormone: histopathological and hormonal changes in the female rat. Br J Exp Pathol 1980; 61: 579–589
Jeffcoate IA, Lucas JMS, Crighton DB. Effects of active immunization of ram lambs and bull calves against synthetic luteinizing hormon-releasing hormone. Theriogenology 1982; 18: 65–77
Chase DJ, Schanbacher BD, Lunstra DD. Effects of pulsatile and continuous luteinizing hormone (LH) infusions on testosterone responses to LH in rams actively immunized against gonadotropin-releasing hormone. Endocrinology 1988; 123: 816–26
Robertson IS, Fraser HM, Inness GM. Effect of immunological castration on sexual and production characteristics of male cattle. Vet Record 1982; 111: 529–31
Adams TE, Adams BM. Feedlot performance of steers and bulls actively immunized against gonadotropin-releasing hormone. J Animal Sci 1992; 70: 1691–8.
Bonneau M, Enright WJ. Immunocastration in cattle and pigs. Livestock Prod Sci 1995; 42: 193–200
Awoniyi CA, Chandrashekar V, Arthur RD, et al. Pituitary and leydig cell function in boars actively immunized against gonadotrophin-releasing hormone. J Reprod Fertil 1988; 84: 295–302
Dowsett KF, Pattie WA, Knott LM, et al. A preliminary study of immunological castration in colts. J Reprod Fertil Suppl 1991; 44: 183–90
Dowsett KF, Tshewang U, Knott LM, et al. Immunocastration of colts and immunospeying of fillies. Immunol Cell Biol 1993; 71: 501–8
Fraser HM. Active immunization of stumptailed macaque monkeys against luteinizing hormone releasing hormone, and its effect on menstrual cycles, ovarian steroids and positive feedback. J Reprod Immunol 1983; 5: 173–83
Huggins C, Grand LG, Brillantes FP. Mammary cancer induced by a single feeding of polynuclear hydrocarons and its suppression. Nature 1961; 189: 204–9
Manni A, Trujillo JE, Pearson OH. Predominant role of prolactin in stimulating the growth of 7, 12-dimethylenz(a)anthracene-induced mammary tumours. Cancer Res 1977; 37: 1216–21
Pearson OH, Molina A, Butler RP, et al. Estrogens and prolactin in mammary cancer. In: Dao TL, editor. Estrogen target tissues and neoplasia. Chicago (IL): University of Chicago Press 1972; 287–305
Jordan VC, Koerner S. Tamoxifen as an anti-tumour agent: role of oestradiol and prolactin. J Endocrinol 1976; 68: 305–11
Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 1989; 16: 83–93
Isaacs JT, Yu GW, Coffey DS. The characterisation of a newly identified, highly metastic variety of Dunning R3327 rat prostatic adenocarcinoma system: the MAT LyLu tumour. Invest Urol 1981; 19: 20–3
Dunning WF. Prostate cancer in the rat. Nat Cancer Inst Mongr 1963; 12: 351–7
Block NL, Camuzzi F, Stover B, Claflin A, et al. Further experience with chemotherapy in the Dunning prostatic adenocarcinoma. Trans Am Assoc Genito-Urin Surg 1979; 70: 57–9
Abel PD, Foster CS, Tebbutt S, et al. Differences in expression of oligosaccharide determinants by phenotypically distinct sublines of the Dunning 3327 rat prostate cancer. J Urol 1990; 144: 760–5
Furst J, Fiebiger E, Jungwirth A, et al. Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgenindependent Dunning R3227-AT2.1 prostate cancer sublines. Prostate 1997; 32: 77–84
Ladd A, Walfield A, Tsong YY, et al. Active immunisation against LHRH alone or combined with LHRH-analogue treatment impedes growth of androgen-dependent prostatic carcinomas. Am J Reprod Immunol 1995; 34: 200–6
Huggins C, Hodges CV. Studies on prostate cancer: effect of castration, of estrogen, and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–397
Aquilina JW, Lipsky JJ, Bostwick DG. Androgen deprivation as a strategy for prostate cancer chemoprevention. J Natl Cancer Inst 1997; 89: 689–96
Walsh PC, Madden JD, Harrod MJ, et al. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974; 291: 944–9
Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213–5
Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995; 23: 43–62
Jackson IM, Matthews MJ, Diver JMJ. LHRH analogues in the treatment of cancer. Cancer Treat Revs 1989; 16: 161–75
Carducci MA, DeWeese TL, Nelson WG, et al. Prostate cancer treatment strategies based on tumor-specific biological principles: future directions. Semin Oncol 1996; 23: 56–62
Konety BR, Getzenberg RH. Novel therapies for advanced prostate cancer. Semin Urol Oncol 1997; 15: 33–42
Andriole GL, Catalona WJ. Prostate carcinoma. Ann Rev Med 1994; 45: 351–9
Moudgal NR, Jeyakumar M, Krishnamurthy HN, et al. Development of male contraceptive vaccine — a perspective. Hum Reprod Update 1997; 3: 335–46
Talwar GP, Singh O, Pal R, et al. Vaccines for control of fertility and hormone-dependent cancers. Int J Immunopharm 1992; 14: 511–4
Pal R, Talwar GP. The LHRH vaccine. In: Talwar GP, Raghupathy R, editors. Birth control vaccines. Austin (TX): R.G. Landes Company, 1995: 63–73
Talwar GP. Fertility regulating and immunotherapeutic vaccines reaching human trials stage. Hum Reprod Update 1997; 3: 301–10
Nasu Y, Timme TL, Yang G, et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostat cancer cells. Nature Med 1998;4: 1062–4
Staney TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Staney TA, et al., editors. Campbells Urology. 6th ed. Philadelphia (PA): WB Saunders, 1992
Craft N, Shostak Y, Carey M, et al. A mechanism for hormoneindependent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase. Nature Med 1999; 5: 280–5
Nelson J. Alternatives to death: understanding androgen-independent prostate cancer. Nature Med 1998; 4: 1011–2
Yang G, Truory LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998; 8: 1873–80
Fielding J, Bist A, Fielding PE. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl Acad Sci U S A 1997; 94: 3753–8
Giovannucci E. Rimm EB, Coditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993; 85: 1571–9
Visakorpi T. New pieces to the prostate cancer puzzle. Nature Med 1999; 5: 264–5
Schneider PG, Jackisch C, Brandt B. Endocrine management of breast cancer. Int J Fertil Menopaus Stud 1994; 39: 115–27
Bajetta E, Zilembo N, DiLeo A, et al. Hormone therapy in advanced breast carcinoma: present and future trends. Cancer Treat Rev 1994; 20: 241–58
Gual C, Garza-Flores J, Menjivar M, et al. Ability of an antilute inizing hormone-releasing hormone vaccine to inhibit gonadotropins in postmenopausal women. Fertil Steril 1997; 67: 404–7
McCann SM, Kimura M, Walezewska A, et al. Hypothalamic control of gonadotrophin secretion by LHRH, ESHRF, NO, cytokines and leptin. Domest Animal Endocrinol 1998; 15: 333–4
Clarke IJ. New concepts in gonadotropin-releasing hormone action on the pituitary gland. Semin Reprod Endocrinol 1987; 5: 345–52
Lincoln GA, Fraser HM. Compensatory response of the LHRH/LH pulse generator following administration of a potent LHRH antagonist in the ram. Endocrinology 1987; 120: 2245–50
Fraser HM. LHRH immunoneutralization: basic studies and prospects for practical application. In: Talwar GP, editor. Immunological approaches to contraception and promotion of fertility. New York: Plenum Press 1986; 125–41
Ferro VA, Stimson WH. Fertility-disrupting potential of synthetic peptides derived from the β-subunit of follicle-stimulating hormone. Am J Reprod Immunol 1998; 40: 187–97
Ben-Josef E, Yang SY, Ji TH, et al. Hormone-refractory prostate cancer clells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999: 161: 970–6
Urbanski HF, White RB, Fernald RD, et al. Regional expression of mRNA encoding a second from of gonadotropin-releasing hormone in the Macaque brain. Endocrinology 1999; 140: 1945–8
McCann SM, Samson WK, Auila MC, et al. The role of brain peptides in the control of anterior pituitary hormone secretion. In: Fink G, Harmar AJ, McKerns KW, editors. Neuroendocrine molecular biology. New York: Plenum Press 1986; 101–12
Knapp RJ, Sternberger LA. High affinity monoclonal antibodies to luteinizing hormone-releasing hormone. Preparation and binding studies. J Neuroimmunol 1984; 6: 361–71
Saavedra R, Bravo PJ, Charli JL, et al. Characterization of high affinity monoclonal antibodies against the luteinizing hormone-releasing hormone. Hybridoma 1987; 6: 663–73
Peching WB. APhase III trial comparing ICI 118630 (Zoladex) with orchidectomy in the managemnet of advanced prostatic cancer. Royal Society of Medicine International Congress and Symposium Series 1987; 125: 27–46
Abbas F, Scardino PT. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am 1996; 23: 587–604
Tunn UW. Neo-adjuvant hormonal therapy of prostate cancer. Urol Res 1997; 25: S57–62
Roach M. Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Eur Urol 1997; 32: 48–54
McLeod DG, Crawford ED, DeAntoni EP. Combined androgen blockade: the gold standard for metastatic prostate cancer. Eur Urol 1997; 32: 70–7
Bare RL, Torti FM. Endocrine therapy of prostate cancer. Cancer Treat Res 1998; 94: 69–87
Hsieh Wen-Son, Simons JW. Systemic therapy of prostate cancer. New concepts from prostate cancer tumour biology. Cancer Treat Rev 1993; 19: 229–60
Middleman MN, Lush RM, Sartor O, et al. Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Cancer Treat Rev 1996; 22: 105–18
Ferro VA, Stimson WH. Effects of adjuvant, dose and carrier pre-sensitization on the immunization efficacy of a GnRH analogue. Drug Design Discov 1996; 14: 179–95
Chamberlain RS. Prospects for the therapeutic use of anti-cancer vaccines. Drugs 1999; 57: 309–25
Jager E, Jager D, Knuth A. Strategies for the development of vaccines to treat breast cancer. Recent Results Cancer Res 1998; 152: 94–102
Kim JJ, Trivedi NN, Wilson DM, et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 1998; 17; 3125-35
Hrouda D, Baban B, Dunsmuir WD, et al. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL 172). Br J Urol 1998; 82; 568–73
Mitchell MS. A personal (biased) perspective on cancer ‘vaccines’. Oncol Res 1997; 9; 459–65
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ferro, V.A., Stimson, W.H. Anti-Gonadotropin Releasing Hormone Vaccines and Their Potential Use in the Treatment of Hormone-Responsive Cancers. BioDrugs 12, 1–12 (1999). https://doi.org/10.2165/00063030-199912010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199912010-00001